BRAF/MEK inhibition in melanoma patients with rare BRAF mutations

被引：0

作者：

Hassel, Jessica Cecile

Menzer, Christian

Menzies, Alexander M.

Carlino, Matteo S.

Long, Georgina V.

Kefford, Richard

Eigentler, Thomas K.

Johnson, Douglas Buckner

Schlaak, Max

Meiss, Frank

Schilling, Bastian

Gutzmer, Ralf

Pfoehler, Claudia

Meier, Friedegund Elke

Zimmer, Lisa

Haalck, Thomas

Thoms, Kai

Kopp-Schneider, Annette

Enk, Alexander

机构：

[1] Univ Heidelberg Hosp, Sect DermatoOncol, Dept Dermatol, Heidelberg, Germany

[2] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[3] Melanoma Inst Australia, Sydney, NSW, Australia

[4] Melanoma Inst Australia, Westmead & Blacktown Hosp, Sydney, NSW, Australia

[5] Univ Sydney, Sydney, NSW, Australia

[6] Univ Sydney, Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[7] Royal North Shore Hosp, Sydney, NSW, Australia

[8] Westmead Hosp, Sydney, NSW, Australia

[9] Macquarie Univ, Sydney, NSW, Australia

[10] Univ Hosp Tubingen, Dept Dermatol, Tubingen, Germany

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] Univ Hosp, Dept Dermatol, Cologne, Germany

[13] Univ Freiburg, Deparment Dermatol & Venereol, Freiburg, Germany

[14] Univ Hosp Wurzburg, Dept Dermatol, Wurzburg, Germany

[15] Hannover Med Sch, Dept Dermatol, Skin Canc Ctr Hannover, Hannover, Germany

[16] Saarland Univ, Dept Dermatol, Med Ctr, Homburg, Germany

[17] Univ Carl Gustav Carus, Dresden, Germany

[18] Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Essen, Germany

[19] Univ Hosp Hamburg Eppendorf, Hamburg, Germany

[20] Univ Hosp Gottingen, Dept Dermatol, Gottingen, Germany

[21] German Canc Res Ctr, Div Biostatist, Heidelberg, Germany

[22] Univ Heidelberg Hosp, Dept Dermatol, Heidelberg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9542

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9542

引用

页数：2

共 50 条

[31] Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi
Megan Othus
Adil I. Daud
Roger S. Lo
Janice M. Mehnert
Thach-Giao Truong
Robert Conry
Kari Kendra
Gary C. Doolittle
Joseph I. Clark
Michael J. Messino
Dennis F. Moore
Christopher Lao
Bryan A. Faller
Rangaswamy Govindarajan
Amy Harker-Murray
Luke Dreisbach
James Moon
Kenneth F. Grossmann
Antoni Ribas
[J]. Nature Medicine, 2020, 26 : 1564 - 1568
[32] BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Van Not, Olivier J.
van den Eertwegh, Alfons J. M.
Haanen, John B.
van Rijn, Rozemarijn S.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Blank, Christian U.
Boers-Sonderen, Marye J.
de Groot, Jan Willem W. B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Bloem, Manja
Piersma, Djura
Stevense-den Boer, Marion
Verheijden, Rik J.
van der Veldt, Astrid A. M.
Wouters, Michel W. J. M.
Blokx, Willeke A. M.
Suijkerbuijk, Karijn P. M.
[J]. CANCER, 2024, 130 (09) : 1673 - 1683
[33] Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
Menzer, Christian
Menzies, Alexander M.
Carlino, Matteo S.
Reijers, Irene
Groen, Emma J.
Eigentler, Thomas
de Groot, Jan Willem B.
van der Veldt, Astrid A. M.
Johnson, Douglas B.
Meiss, Frank
Schlaak, Max
Schilling, Bastian
Westgeest, Hans M.
Gutzmer, Ralf
Pfoehler, Claudia
Meier, Friedegund
Zimmer, Lisa
Suijkerbuijk, Karijn P. M.
Haalck, Thomas
Thoms, Kai-Martin
Herbschleb, Karin
Leichsenring, Jonas
Menzer, Alexander
Kopp-Schneider, Annette
Long, Georgina V.
Kefford, Richard
Enk, Alexander
Blank, Christian U.
Hassel, Jessica C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (33) : 3142 - +
[34] Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition
Allen, Amy
Qin, Alice Can Ran
Raj, Nitya
Wang, Jiawan
Uddin, Sharmeen
Yao, Zhan
Tang, Laura
Meyers, Paul A.
Taylor, Barry S.
Berger, Michael F.
Yaeger, Rona
Reidy-Lagunes, Diane
Pratilas, Christine A.
[J]. PLOS ONE, 2019, 14 (06):
[35] Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, Antoni
Lawrence, Donald
Atkinson, Victoria
Agarwal, Sachin
Miller, Wilson H., Jr.
Carlino, Matteo S.
Fisher, Rosalie
Long, Georgina V.
Hodi, F. Stephen
Tsoi, Jennifer
Grasso, Catherine S.
Mookerjee, Bijoyesh
Zhao, Qing
Ghori, Razi
Moreno, Blanca Homet
Ibrahim, Nageatte
Hamid, Omid
[J]. NATURE MEDICINE, 2019, 25 (06) : 936 - +
[36] Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas
Donald Lawrence
Victoria Atkinson
Sachin Agarwal
Wilson H. Miller
Matteo S. Carlino
Rosalie Fisher
Georgina V. Long
F. Stephen Hodi
Jennifer Tsoi
Catherine S. Grasso
Bijoyesh Mookerjee
Qing Zhao
Razi Ghori
Blanca Homet Moreno
Nageatte Ibrahim
Omid Hamid
[J]. Nature Medicine, 2019, 25 : 936 - 940
[37] Clinical Outcomes of Combined BRAF and MEK Inhibition With Stereotactic Radiation for BRAF Mutant Melanoma Brain Metastases
Echevarria, M.
Ahmed, K. A.
Patel, B.
Abuodeh, Y. A.
Naghavi, A. O.
Sarangkasiri, S.
Johnstone, P. A. S.
Etame, A. B.
Yu, H. M.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E115 - E116
[38] Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases
Patel, Bindiya G.
Ahmed, Kamran A.
Johnstone, Peter A. S.
Yu, Hsiang-Hsuan Michael
Etame, Arnold B.
[J]. MELANOMA RESEARCH, 2016, 26 (04) : 382 - 386
[39] Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
Rivalland, Gareth
Mitchell, Paul
[J]. LANCET ONCOLOGY, 2016, 17 (07): : 860 - 862
[40] The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
Chen, Peng
Chen, Fucaho
Zhou, Benhong
[J]. CUTANEOUS AND OCULAR TOXICOLOGY, 2019, 38 (02) : 105 - 111

← 1 2 3 4 5 →